CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: January 4, 2017
Result type: Reports
Project Number: SR0514-000
Product Line: Reimbursement Review

Generic Name: Brexpiprazole

Brand Name: Rexulti

Manufacturer: Otsuka-Lundbeck

Therapeutic Area: schizophrenia

Indications: Schizophrenia

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: November 22, 2017

Recommendation Type: Reimburse with clinical criteria and/or conditions